Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Gespeichert in:
Autoren: | , , , , , , , , , , , , , |
---|---|
格式: | Artikel |
語言: | 英语 |
出版: |
Philipps-Universität Marburg
2023
|
主題: | |
在線閱讀: | PDF-Volltext |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
No abstracts were found for this record.